{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:13Z","timestamp":1787237953224,"version":"build-2736575974"},"reference-count":73,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,6]]},"DOI":"10.14797\/mdcvj.1175","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:17:39Z","timestamp":1670311059000},"page":"5-16","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacotherapy for Essential Hypertension: A Brief Review"],"prefix":"10.14797","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-1646","authenticated-orcid":false,"given":"Behnam","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7153-3790","authenticated-orcid":false,"given":"Eleonora","family":"Avenatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-2269","authenticated-orcid":false,"given":"Khurram","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"10304","key":"key20221206071711_B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration","year":"2021","journal-title":"Lancet"},{"issue":"10100","key":"key20221206071711_B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD 2016 Risk Factors Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"key20221206071711_B3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015","volume":"317","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"key20221206071711_B4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population","volume":"291","year":"2004","journal-title":"JAMA"},{"issue":"9349","key":"key20221206071711_B5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"key20221206071711_B6","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2018.07.008","article-title":"Prevention and Control of Hypertension: JACC Health Promotion Series","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20221206071711_B7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis","volume":"178","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"19","key":"key20221206071711_B8","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"key20221206071711_B9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221206071711_B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"key20221206071711_B11","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1001\/jama.294.19.2455","article-title":"Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial","volume":"294","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"key20221206071711_B12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archinternmed.2009.470","article-title":"Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study","volume":"170","year":"2010","journal-title":"Arch Intern Med"},{"issue":"2","key":"key20221206071711_B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.1958.02990020025004","article-title":"Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents","volume":"166","year":"1958","journal-title":"J Am Med Assoc"},{"issue":"11","key":"key20221206071711_B14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jama.1967.03130240070013","article-title":"Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg","volume":"202","author":"Effects of treatment on morbidity in hypertension","year":"1967","journal-title":"JAMA"},{"issue":"7","key":"key20221206071711_B15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.1970.03170330025003","article-title":"II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg","volume":"213","author":"Effects of treatment on morbidity in hypertension","year":"1970","journal-title":"JAMA"},{"issue":"23","key":"key20221206071711_B16","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/jama.1979.03300230018021","article-title":"I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group","volume":"242","author":"Five-year findings of the hypertension detection and follow-up program","year":"1979","journal-title":"JAMA"},{"issue":"6488","key":"key20221206071711_B17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"Medical Research Council Working Party","volume":"291","author":"MRC trial of treatment of mild hypertension: principal results","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6687","key":"key20221206071711_B18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.298.6687.1552","article-title":"Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly","volume":"298","year":"1989","journal-title":"BMJ"},{"issue":"24","key":"key20221206071711_B19","first-page":"3255","article-title":"Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group","volume":"265","author":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension","year":"1991","journal-title":"JAMA"},{"issue":"9118","key":"key20221206071711_B20","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"9489","key":"key20221206071711_B21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"issue":"23","key":"key20221206071711_B22","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"issue":"17","key":"key20221206071711_B23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"key20221206071711_B24","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"key20221206071711_B25","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.1993.03510060059034","article-title":"Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group","volume":"270","year":"1993","journal-title":"JAMA"},{"issue":"6","key":"key20221206071711_B26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","year":"2020","journal-title":"J Hypertens"},{"issue":"33","key":"key20221206071711_B27","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","year":"2018","journal-title":"Eur Heart J"},{"issue":"13","key":"key20221206071711_B28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"issue":"7653","key":"key20221206071711_B29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","year":"2008","journal-title":"BMJ"},{"key":"key20221206071711_B30","doi-asserted-by":"crossref","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","year":"2009","journal-title":"BMJ"},{"issue":"10022","key":"key20221206071711_B31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"key20221206071711_B32","article-title":"First-line drugs for hypertension","volume":"4","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"key20221206071711_B33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"key20221206071711_B34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/HYPERTENSIONAHA.107.096933","article-title":"Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension","volume":"51","year":"2008","journal-title":"Hypertension"},{"issue":"4","key":"key20221206071711_B35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000368513","article-title":"Treatment of Hypertension: Favourable Effect of the Twice-Daily Compared to the Once-Daily (Evening) Administration of Perindopril and Losartan","volume":"40","year":"2015","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"key20221206071711_B36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/07420520500180488","article-title":"Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects","volume":"22","year":"2005","journal-title":"Chronobiol Int"},{"issue":"7","key":"key20221206071711_B37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3109\/07420528.2011.589935","article-title":"Chronotherapy with valsartan\/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing","volume":"28","year":"2011","journal-title":"Chronobiol Int"},{"issue":"6","key":"key20221206071711_B38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3109\/07420528.2010.489167","article-title":"Chronotherapy with valsartan\/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing","volume":"27","year":"2010","journal-title":"Chronobiol Int"},{"issue":"2","key":"key20221206071711_B39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/HJH.0000000000000397","article-title":"Time of administration important? Morning versus evening dosing of valsartan","volume":"33","year":"2015","journal-title":"J Hypertens"},{"issue":"8 Pt 1","key":"key20221206071711_B40","first-page":"806","article-title":"Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate","volume":"12","year":"1999","journal-title":"Am J Hypertens"},{"issue":"4","key":"key20221206071711_B41","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.118.11101","article-title":"Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure","volume":"72","year":"2018","journal-title":"Hypertension"},{"issue":"10","key":"key20221206071711_B42","article-title":"Evening versus morning dosing regimen drug therapy for hypertension","volume":"2011","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20221206071711_B43","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(22)01786-X","article-title":"Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"key20221206071711_B44","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archinte.164.7.722","article-title":"How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials","volume":"164","year":"2004","journal-title":"Arch Intern Med"},{"issue":"7","key":"key20221206071711_B45","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in Hypertension","volume":"124","year":"2019","journal-title":"Circ Res"},{"issue":"4","key":"key20221206071711_B46","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11906-013-0353-4","article-title":"Generic drugs for hypertension: are they really equivalent?","volume":"15","year":"2013","journal-title":"Cur Hypertens Rep"},{"issue":"18","key":"key20221206071711_B47","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/archinte.1997.00440390066010","article-title":"A physician survey on generic drugs and substitution of critical dose medications","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"issue":"5","key":"key20221206071711_B48","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11096-006-9043-5","article-title":"Patients\u2019 attitudes towards and experiences of generic drug substitution in Norway","volume":"28","year":"2006","journal-title":"Pharm World Sci"},{"issue":"21","key":"key20221206071711_B49","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/jama.2008.758","article-title":"Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis","volume":"300","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"key20221206071711_B50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10654-015-0104-8","article-title":"Generic versus brand-name drugs used in cardiovascular diseases","volume":"31","year":"2016","journal-title":"Eur J Epidemol"},{"issue":"1","key":"key20221206071711_B51","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1038\/s41598-020-62318-y","article-title":"Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study","volume":"10","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"key20221206071711_B52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/CM9.0000000000001360","article-title":"Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China","volume":"134","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"key20221206071711_B53","article-title":"Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China","volume":"13","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20221206071711_B54","article-title":"Generic vs brand-name drugs for the treatment of hypertension","volume":"36","year":"2018","journal-title":"J Hypertens"},{"issue":"9311","key":"key20221206071711_B55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"key20221206071711_B56","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"691","key":"key20221206071711_B57","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3399\/bjgp20X708053","article-title":"Diagnosis and management of hypertension in adults: NICE guideline update 2019","volume":"70","year":"2020","journal-title":"Br J Gen Pract"},{"issue":"11","key":"key20221206071711_B58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/jhh.2016.6","article-title":"Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program","volume":"30","author":"MINISAL-SIIA Study Group","year":"2016","journal-title":"J Hum Hypertens"},{"issue":"2","key":"key20221206071711_B59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.113.00687","article-title":"Measuring, analyzing, and managing drug adherence in resistant hypertension","volume":"62","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"key20221206071711_B60","article-title":"Obstructive Sleep Apnea, Hypertension, and Cardiovascular Risk: Epidemiology, Pathophysiology, and Management","volume":"22","year":"2020","journal-title":"Curr Cardiol Rep"},{"issue":"10008","key":"key20221206071711_B61","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"key20221206071711_B62","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment)","volume":"71","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"key20221206071711_B63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/jhh.2014.64","article-title":"Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis","volume":"29","year":"2015","journal-title":"J Hum Hypertens"},{"issue":"12","key":"key20221206071711_B64","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00392-011-0335-y","article-title":"Sympatho-renal axis in chronic disease","volume":"100","year":"2011","journal-title":"Clin Res Cardiol"},{"issue":"15","key":"key20221206071711_B65","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"key20221206071711_B66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.117.09086","article-title":"Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up","volume":"69","year":"2017","journal-title":"Hypertension"},{"issue":"3","key":"key20221206071711_B67","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/ajh\/hpz157","article-title":"Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension","volume":"33","year":"2020","journal-title":"Am J Hypertens"},{"issue":"6","key":"key20221206071711_B68","article-title":"Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients","volume":"6","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"key20221206071711_B69","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20221206071711_B70","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/oby.21107","article-title":"GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond","volume":"23","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"key20221206071711_B71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11883-022-01041-7","article-title":"Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management","volume":"24","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"key20221206071711_B72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"key20221206071711_B73","article-title":"Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists","volume":"160","year":"2020","journal-title":"Pharmacol Res"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:18:11Z","timestamp":1670311091000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1175\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12,6]]}},"alternative-id":["10.14797\/mdcvj.1175"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1175","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}